Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2006

View Archived Issues

GYKI-16084 improves symptoms in benign prostatic hyperplasia

Phase I study data support fixed dosing of ABT-751 in cancer patients

Effect of sildenafil on peak systolic velocity a mechanism of erection improvement

Advanced Cell Technology announces timetables for IND filings in key therapeutic programs

Advaxis reports update of Listeria-based vaccines

Hemispherx Biopharma to conduct influenza vaccine/immunopotentiation phase II clinical trial

PhytoMedical Technologies' BDC-O3 holds potential for atherosclerosis

Patient enrollment complete for X-Cell Medical's ETHOS II estradiol-eluting stent trial

Marshall Edwards achieves SPA for pivotal trial of phenoxodiol

Patient enrollment complete in phase III trial of telavancin for cSSSI

More positive data reported for Nymox's BPH drug candidate

BioMS Medical receives approval to begin phase II RRMS trial

Phase II trial of Manhattan Pharmaceutical's obesity drug candidate cleared in Switzerland

Shire provides update on Elaprase's registration process

Migenix receives approval in Canada to begin phase II trial for HCV

Intercept Pharmaceuticals' INT-747 well tolerated in phase Ia study

Lexiva has comparable activity to the preferred HIV protease inhibitor Kaletra

TC-1734 reaches endpoints in age-associated memory impairment phase II trials

Novel antiinfective agents disclosed in recent patent literature

Novel treatment options for metabolic disorders described in recent patents

FDA approves Azilect for Parkinson's disease

Promising camptothecin derivatives developed at Bristol-Meyers Squibb

Actilon granted fast track designation in U.S. as HCV therapy

FDA committee unanimously supports efficacy of Gardasil clinical data

Antisense oligomers effective against different strains of the influenza A virus in vitro

Novel triple reuptake inhibitor shows antidepressant activity in animal models

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...